openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizie

News

Discover

Markets

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizie

entrectinib — news, coverage & facts — IJR

|NewsJournalsTopicentrectinib

Topic

entrectinib

3 members

Feed News Media Community Answers Map About

3 memberscoverage spread: L0/C75/R25

Comments

Ask this entity anything:

Free account · your comment posts right after signup

Health
GSK earns FDA approval for Jideytro
GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.
9 sources

Facts from Wikidata (CC0).

Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).

Read the full article →